Dow Chemical’s silicone business play: what it means for medtech

Heather Thompson, Senior Editor

Dow Chemical as of mid-2016 became 100% owner of Dow Corning’s silicones business.

The move created both an opportunity and challenge because it represents a marriage of organic chemistry and inorganic chemistry. How can the two complement each other and drive innovation? And how will the deal affect the medical device industry?

MDO caught up with Dow Corning officials this week at the annual MD&M West conference and expo in Anaheim, California, where they’re exhibiting at Booth #1921. Here’s what Gary Lord, global strategic marketing manager for Dow Corning Silicone, and Roger Hendrick, technical service and development for medical markets at Dow Corning, had to say:

MDO: How do you see that playing out in the medical device space?

Lord: From a market and sort of an industry perspective, I think what we’re looking at here is an industry that is looking for maximizing the solutions that they can gain from suppliers to look at innovation with materials that have a good proven performance and a long history in terms of their usage, but be able to put them together in new and innovative ways. That’s what for me is the exciting opportunity to be out here with bringing the silicone chemistry of Dow Corning truly into Dow Chemical and blending that with the organic chemistry that they have.

Get the full story on our sister site, Medical Design & Outsourcing.

The post Dow Chemical’s silicone business play: what it means for medtech appeared first on MassDevice.

from MassDevice http://ift.tt/2kYClSI